Cardiovascular disease has become the global leading burden of disease and it is currently the most serious public health problem. Soluble guanylate cyclase agonists play an important role in regulating the cardiovascular system in the nitric oxide-soluble guanylate cyclase-cyclic guanosine phosphate signaling pathway. More and more studies have shown that soluble guanylate cyclase agonists have protective effects on cardiomyocyte hypertrophy, myocardial remodeling and myocardial ischemia-reperfusion injury, and its potential mechanism remains to be explored in depth. Soluble guanylate cyclase agonists can reduce cardiovascular deaths and re-hospitalization for heart failure. This article focuses on the protective mechanism of soluble guanylate cyclase agonists in cardiovascular diseases such as hypertension, pulmonary hypertension and heart failure, with the aim of deepening the understanding of soluble guanylate cyclase agonists.